NSAIDs and the gastrointestinal tract: an update on recent progress.
This article outlines the mechanisms involved in specific cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibition as they relate to the safety of nonsteroidal anti-inflammatory drug (NSAID) use. New advancements in COX-2 technology appear to improve the safety profile of NSAID therapy. Gastroenterologic issues such as ulcer disease and liver disease as related to these novel new medications are reviewed.
Silverman
G J
GJ
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004064:Digestive System / Q000187:drug effects; D006801:Humans; D008099:Liver / Q000187:drug effects; D012449:Safety
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors